Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
 
 

Neoadjuvant Immunotherapy in Genitourinary Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (20 October 2024) | Viewed by 521

Special Issue Editors


E-Mail Website
Guest Editor
Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, 00161 Rome, Italy
Interests: urology; uro-oncology; andrology; kidney stones; urolithiasis; incontinence; CEUS; contrast-enhanced ultrasound; kidney cancer; bladder cancer; prostate cancer; penile cancer; reflux

E-Mail Website
Guest Editor
1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
Interests: uro-oncology

E-Mail Website
Guest Editor
1. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
2. Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy
Interests: cell cycle dependent kinase (CDK); retinoblastoma protein family; cancer therapy; mesothelioma; CDK9; Rb2
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genitourinary (GU) malignancies affect many people worldwide, with millions of new cases diagnosed annually. In recent decades, our understanding of cancer and its pathophysiology has evolved. It has been well established that cancer cells have developed multiple mechanisms to avoid the immune system. 

The use of immunotherapy in the preoperative or neoadjuvant setting is supported by preclinical studies showing that stronger and broader immune responses can be generated when immunotherapy is administered with the primary tumor and/or regional lymph nodes intact. By interfering with pathways in the tumor microenvironment, immune checkpoint inhibitors (ICIs) allow the immune system to “ramp up” and effectively target malignant cells. 

This Special Issue delves into the role of immunotherapy in the treatment of GU malignancies, specifically urothelial, renal, prostate, and other rarer tumors. The goal is to enhance “precision therapy” evidence to increase overall survival and progression-free survival. 

Dr. Antonio Tufano
Dr. Nadia Cordua
Prof. Dr. Antonio Giordano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immune checkpoint inhibitor
  • bladder cancer
  • urothelial cancer
  • kidney cancer
  • renal cell carcinoma
  • prostate cancer
  • testicular cancer
  • penile cancer
  • adrenocortical carcinoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop